EAPH (Easton Pharmaceuticals) Retained Earnings: $-40.08 Mil (As of Sep. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EAPH Easton Pharmaceuticals Inc EAPH
12 GF Score
Price $0.00
View Full Analysis

What is Easton Pharmaceuticals Retained Earnings?

Easton Pharmaceuticals EAPH -95.00% 12 Retained Earnings is $-40.08 Mil as of Sep. 2021. GuruFocus rates EAPH with a GF Score™ of 12/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Easton Pharmaceuticals's retained earnings for the quarter that ended in Sep. 2021 was $-40.08 Mil.

Easton Pharmaceuticals's quarterly retained earnings declined from Mar. 2021 ($-39.92 Mil) to Jun. 2021 ($-40.00 Mil) and declined from Jun. 2021 ($-40.00 Mil) to Sep. 2021 ($-40.08 Mil).

Easton Pharmaceuticals's annual retained earnings declined from Dec. 2018 ($-39.22 Mil) to Dec. 2019 ($-39.63 Mil) and declined from Dec. 2019 ($-39.63 Mil) to Dec. 2020 ($-39.82 Mil).


Easton Pharmaceuticals  (OTCPK:EAPH) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Easton Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Easton Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easton Pharmaceuticals Retained Earnings Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Retained Earnings
Get a 7-Day Free Trial -29.13 -33.11 -39.22 -39.63 -39.82

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.63 -39.82 -39.92 -40.00 -40.08
EAPH
12GF Score
Easton Pharmaceuticals Inc EAPH
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easton Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-40.08 Mil mean?
Easton Pharmaceuticals (EAPH) has a Retained Earnings of $-40.08 Mil as of Sep. 2021. Retained earnings is the amount of net income not issued to shareholders. View historical data on Easton Pharmaceuticals and its competitors.
Is Easton Pharmaceuticals' Retained Earnings too high?
Easton Pharmaceuticals' current Retained Earnings is $-40.08 Mil. Overall, Easton Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Easton Pharmaceuticals' Retained Earnings compare to FPSUF and GCAN?
Easton Pharmaceuticals' Retained Earnings of $-40.08 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Easton Pharmaceuticals and its competitors. Easton Pharmaceuticals's current Retained Earnings is $-40.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easton Pharmaceuticals stock overvalued right now?
Easton Pharmaceuticals (EAPH) has a current Retained Earnings of $-40.08 Mil. The current Retained Earnings is $-40.08 Mil. Easton Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Easton Pharmaceuticals (EAPH), the current Retained Earnings is $-40.08 Mil as of Sep. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Easton Pharmaceuticals Business Description

Address 2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.
12GF Score

Get the complete analysis for EAPH

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price